fda warning letters glp-1 september 2025 news Trends In FY FDA COMES FOR NOVO DRAMA.

It can be argued that significant effects were seen largely due to the homogeneous participant pool that started out with decreased metabolic health, and that results may not apply to healthy weight individuals

Why Ulcerative Colitis Was the Only Use Evaluated FDA narrowed the review to the supported nomination The agency evaluated BPC-157 free base and acetate for ulcerative colitis because that was the use for which it determined there was enough nomination information to conduct the committee review

Research published in the American Journal of Respiratory and Critical Care Medicine has found that people with asthma and chronic obstructive pulmonary disease (COPD) often show significantly lower glutathione levels in their airway fluid compared to healthy individuals

Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results